Researchers found that men whose testosterone fell following radiation therapy were more likely to experience an increase in prostate-specific antigen (PSA), often indicating cancer recurrence. This discovery may lead doctors to use testosterone levels as a guide for treatment decisions.
LDK378 shows encouraging activity in patients with ALK+ non-small cell lung cancer, including those who no longer respond to crizotinib. The compound is well-tolerated and its optimal dose is being further tested.
A study found that combining lapatinib and pazopanib did not improve outcomes for patients with inflammatory breast cancer, despite increased side effects. Lapatinib was shown to be an effective treatment option for women with this disease.
A new analysis from Fox Chase Cancer Center suggests that high costs can limit access to potentially life-saving genetic testing for cancer-causing genes. Patients who are more at risk of certain cancers may be willing to pay higher costs, but others may avoid testing due to cost concerns.
Fox Chase researchers found that patients' socioeconomic status influences their treatment choices, with those having higher incomes opting for more effective but expensive treatments. This study highlights the need for policymakers to consider cost sensitivity in cancer care.
A recent study from Fox Chase Cancer Center found that nearly half of the research presented at ASCO's annual meeting came from researchers with industry ties. The study suggests a growing dependence on industry funding for cancer research, highlighting the need to investigate potential conflicts of interest.
A new treatment regimen, accelerated MVAC, has been shown to provide comparable benefits to standard chemotherapy without the same toxicity. This accelerated schedule of six weeks has improved response rates and tolerability for patients with muscle-invasive bladder cancer.
Robert F. Ozols, a leading expert in ovarian cancer research, will be honored with the American Society of Clinical Oncology's 2012 Distinguished Achievement Award. He made significant contributions to advancing chemotherapy research and overcoming drug resistance.
Researchers investigated whether preoperative imaging differed between black and white women with breast cancer. They found no disparity in the use of imaging, contrary to some earlier studies. However, they did note that women from more educated areas were more likely to receive certain types of imaging.
Researchers at Fox Chase Cancer Center have developed a new approach to overcome drug resistance in colorectal cancer patients. Their novel drug, ARI-4175, has shown promise in extending survival by enlisting the body's own immune system to reject tumors.
Researchers at Fox Chase Cancer Center have developed a new cell and animal model of inflammatory breast cancer, which may provide a better understanding of the disease and help with developing effective interventions. The model recapitulates aggressive metastasis and cancer stem cell activity associated with poor outcomes in patients.
Researchers at Fox Chase Cancer Center have identified a new compound that targets a key pathway in lymphoma, suggesting it could be the first to hit this critical mechanism. The study found that certain types of lymphoma cells are more vulnerable to the effects of the compound, making them potential candidates for early clinical trials.
Scientists at Fox Chase Cancer Center discovered a link between estrogen and tobacco smoke, suggesting that new therapies targeting estrogen metabolism may help prevent or treat lung cancer. Estrogen metabolites increase in the lungs of mice exposed to tobacco smoke, promoting cell growth and damage.
Scientists at Fox Chase Cancer Center found that defects in ribosomal proteins can lead to blood and other cancers. Inactivating L22, a key protein, triggered changes in cell signaling pathways associated with inflammation, which may be targeted for cancer treatment.
A study at Fox Chase Cancer Center found that patients with a specific variant of the CYP1B1 gene have a longer time-to-recurrence of squamous cell carcinoma of the head and neck. This discovery could lead to tailored treatment approaches for affected individuals.
Scientists at Fox Chase Cancer Center have discovered compounds that enhance the effects of gemcitabine, improving its ability to kill pancreatic cancer cells. This breakthrough could lead to a lower dose of chemotherapy with fewer side effects, potentially increasing survival rates for patients.
Researchers found that patients with high levels of Aurora-A protein had shorter survival after surgery compared to those with normal levels. This suggests Aurora-A plays a role in head and neck cancer development and could serve as a new treatment target.
Researchers at Fox Chase Cancer Center found that survivin levels were associated with longer disease-free survival and better response to chemotherapy in patients with pancreatic cancer. The study suggests that survivin could be a useful tool for identifying patients who may benefit from specific treatments.
Researchers at Fox Chase Cancer Center have identified two proteins that could restore treatment sensitivity to hormone-resistant breast cancer cells. These proteins may help develop a new therapy combining estrogen and interferon-alpha, offering more treatment options for patients with resistant disease.
Dr. Beatrice Mintz has made significant contributions to cancer research, including her work on developmental biology and genetics. Her groundbreaking studies have helped shape our understanding of stem cell behavior and the tumor microenvironment.
Fox Chase Cancer Center is leading efforts to establish national standards for survivorship care, citing the need for comprehensive plans and guidelines. The Center's own survivorship care plan will be tailored to each patient, summarizing therapy and making recommendations based on their specific case.
A new phase 3 clinical trial shows that targeted therapy bevacizumab effectively delays the progression of advanced ovarian cancer. Patients with newly diagnosed advanced ovarian cancer can now benefit from an additional treatment option, alongside surgery and chemotherapy.
Women with newly diagnosed inflammatory breast cancer who have stray tumor cells in their blood should receive aggressive treatment, regardless of imaging results. Researchers found no correlation between circulating tumor cells and survival rates in these patients.
Researchers found that between 1992 and 2005, the percentage of patients who had multiple imaging visits nearly quadrupled, from 4.9% to 19.4%. A single imaging visit increasingly includes multiple types of imaging, with the rate rising from 4.3% to 27.1%.
A new study creates a comprehensive library of 178 kinase inhibitors targeting 300 enzymes, including those critical for cancer and other diseases. This library will aid researchers in developing cancer drugs that block specific kinases while minimizing side effects.
A study by Fox Chase researchers found that a portion of the prostate bed is outside IMRT treatment margins in post-prostatectomy patients, suggesting too little treatment in the target area and too much in surrounding structures. The Calypso system helps ensure precise delivery within narrow treatment margins.
Researchers found that patients with a family history of prostate cancer had equivalent PSA controls, freedom from metastasis, and overall survival following radiotherapy. This suggests that more aggressive treatment may not be necessary for these patients.
Fox Chase researchers have developed a new nomogram that uses factors like PSA level, Gleason score, and interval to biochemical failure to estimate a patient's five- and 10-year risk of death. The tool helps doctors identify patients at highest risk of dying from prostate cancer.
Researchers found that Fox Chase Cancer Center's pathologists can better predict prostate cancer recurrence using their own Gleason scores than those from other institutions. This accuracy enables doctors to advise patients on the best treatment options and outcomes.
A study by Fox Chase Cancer Center found that sentinel lymph node biopsy can predict cancer recurrence and guide treatment for Merkel cell carcinoma patients. The procedure led to lower risk of cancer recurrence and improved survival rates in two-year follow-up.
Researchers at Fox Chase Cancer Center have developed a new technique for delivering radiation therapy using a multileaf collimator, significantly reducing treatment time and minimizing radiation exposure to surrounding tissues. The new method achieves better target coverage and dose sharpness than traditional CyberKnife technology.
Researchers at Fox Chase Cancer Center found that IMRT improved treatment outcomes for patients with extranodal lymphoma of the head and neck, with minimal side effects. The study showed high response rates and no severe dry mouth, relapses, or tissue abnormalities.
Scientists at Fox Chase Cancer Center have identified a novel approach to develop targeted cancer therapies by reversing silenced genes through demethylation. The study suggests that specific proteins, such as thymine DNA glycosylase, can actively remove methyl groups from DNA.
Researchers at Fox Chase Cancer Center discovered that a low lymphocyte count is a simple and effective prognostic indicator in patients with renal cell carcinoma. The study found that lower lymphocyte levels are associated with a higher tumor grade, pathologic tumor stage, presence of distant metastases, and lower overall survival rate.
Researchers at Fox Chase Cancer Center have found a less toxic combination of erlotinib and bevacizumab to be effective in treating advanced non-small cell lung cancer. The treatment regimen resulted in improved progression-free survival and overall survival rates, with fewer patients experiencing severe side effects.
A study found that low lymphocyte counts before surgery are associated with poor prognosis, higher tumor grades, and lower overall survival rates. The researchers suggest that this test could help doctors individualize therapies and change clinical decisions.
Research suggests that doctors should tailor treatment to specific qualities of second tumor, regardless of whether it's old or new. Studies found that 89% of recurring tumors differed in at least one characteristic compared to the original tumor.
Researchers identified Abcc10 as a key player in resisting certain anticancer drugs, including taxanes. Blunting its activity may help counteract resistance and make these drugs more effective, providing hope for improved treatment options.
Researchers from Fox Chase Cancer Center investigated the effectiveness of active surveillance in patients with small renal masses. They found that in select patients, active surveillance may be a viable option when surgery is risky due to poor health or advanced age.
A new study examines the trend of radical nephrectomy rates in patients with clinically localized renal masses and finds that despite guidelines recommending kidney preservation, laparoscopic procedures have become more prevalent than expected. This shift may lead to increased morbidity and mortality due to chronic renal insufficiency.
A recent study published at the American Radium Society Annual Meeting found that aspirin use lowers the risk of cancer recurrence in prostate cancer patients who have received radiotherapy. After 10 years, men taking aspirin had a 31% lower rate of biochemical failure compared to non-aspirin users.
Researchers found that higher levels of perceived stress and depressive symptoms are associated with greater VEGF expression in tumor tissue, leading to shorter disease-free survival. The study suggests psychosocial interventions may have limited impact on patients with advanced cancer.
Researchers at Fox Chase Cancer Center found that naproxen and its derivative NO-naproxen reduce tumor formation in mutant mice. The data also suggests that naproxen blocks a key step in colon cancer formation, which could lead to the development of new chemopreventive agents.
Researchers found that fish oil increases expression of genes related to cellular specialization, differentiation, and immune defenses against tumors. However, it also triggers counterproductive immune responses like inflammation and allergic reactions.
Researchers at Fox Chase Cancer Center have discovered a gene expression pattern in breast tissue that differs between post-menopausal women who had children and those who did not. This genomic signature may help scientists understand why pregnancy reduces breast cancer risk and develop chemopreventive strategies.
Researchers at Fox Chase Cancer Center have found a direct correlation between the expression of a key tumor suppressor protein and premature aging in mice. The study suggests that blocking cell proliferation induced by the p16 protein leads to features of premature aging, not just molecular damage.
Researchers at Fox Chase Cancer Center have developed a screen to identify proteins that work with histone deacetylases and DNA methyltransferases to repress gene expression. The method revealed 128 factors involved in regulating gene expression, potentially leading to broader cancer therapies
Fox Chase researchers identify retinoic acid as a promising therapy for early-stage breast cancer, inhibiting cell growth and proliferation. The study's findings suggest that the treatment may be effective in stopping tumor progression at its earliest stages.
Researchers found that a common variant of the p53 gene increases inflammatory responses following DNA damage, making African Americans more susceptible to certain diseases and cancers. The proline variant interacts with NF-kB, a protein complex regulating the immune response, leading to enhanced activation of inflammation genes.
Researchers at Fox Chase Cancer Center have discovered two novel genetic markers associated with earlier time to prostate cancer diagnosis among African American men. Genetic variations in miRNA binding sites, particularly in genes IL-16 and IL-18, were found to increase the risk of early diagnosis.